Passive immunization using antibodies against tau epitopes is the most widely studied therapeutic strategy in MAPT mouse models (Figure 5A), and several antibodies within this category have been tested in or are in clinical trials for tauopathies. This evidence concerns the gene MAPT and tauopathy.